MARKET

BDSX

BDSX

BIODESIX INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.82
+0.17
+0.96%
Closed 16:00 11/24 EST
OPEN
17.82
PREV CLOSE
17.65
HIGH
18.40
LOW
17.66
VOLUME
203.50K
TURNOVER
--
52 WEEK HIGH
19.13
52 WEEK LOW
10.85
MARKET CAP
470.82M
P/E (TTM)
-0.8219
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Morgan Stanley Initiates Coverage On Biodesix with Overweight Rating, Announces Price Target of $20
Morgan Stanley initiates coverage on Biodesix (NASDAQ:BDSX) with a Overweight rating and announces Price Target of $20.
Benzinga · 1d ago
The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates
Biotech stocks came under pressure in the week ended Nov. 20, reversing course from the previous week.
Benzinga · 2d ago
The Daily Biotech Pulse:Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17)
Benzinga · 6d ago
MediaAlpha Stock Rockets 64% as Root Insurance and Other IPOs Fall Flat
The stock shined as other IPOs, including the larger Root Insurance, fell flat.
Barrons.com · 10/28 20:36
Auto-Insurance Disrupter Root Is Going Public Today. It’s Valued at $6.7 Billion.
Root Insurance raised $724.4 million after boosting the size of its initial public offering and pricing shares above the expected range.
Barrons.com · 10/28 14:32
Biodesix Priced 4M Share IPO @$18/Share
Biodesix, Inc. (NASDAQ: BDSX) ("Biodesix") today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.
Benzinga · 10/28 09:17
Biodesix prices IPO at $18/share, trades today
Lung cancer diagnostics company, Biodesix (BDSX) has priced initial public offering of ~4.17M common shares at $18/share.Underwriters' over-allotment is an additional 600K shares.Trading commences today on Nasdaq.Offering is expected to close
Seekingalpha · 10/28 09:15
Biodesix Announces Pricing of Initial Public Offering
Biodesix, Inc. (Nasdaq: BDSX) ("Biodesix") today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on The Nasdaq Global Market on October 28, 2020, under the symbol "BDSX." The offering is expected to close on October 30, 2020, subject to the satisfaction of customary closing conditions. In addition, Biodesix has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Business Wire · 10/28 09:00
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BDSX. Analyze the recent business situations of BIODESIX INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+1.03%
Healthcare Providers & Services
+0.67%
Key Executives
Chairman/Director
Robert Cawthorn
Chief Executive Officer/Director
David Brunel
Founder/Chief Technology Officer
Heinrich Roder
Chief Financial Officer/Primary Contact
Robin Cowie
Other
Paul Beresford
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BDSX
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Biodesix Inc stock information, including NASDAQ:BDSX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSX stock methods without spending real money on the virtual paper trading platform.